Ranchi News Desk

Hypertrophic Cardiomyopathy Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

 Breaking News
  • No posts were found

Hypertrophic Cardiomyopathy Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

November 08
16:04 2021
Hypertrophic Cardiomyopathy Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working
DelveInsight Business Research LLP
DelveInsight’s ‘Hypertrophic Cardiomyopathy (HCM)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Hypertrophic Cardiomyopathy (HCM), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Hypertrophic Cardiomyopathy – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Hypertrophic Cardiomyopathy – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Hypertrophic Cardiomyopathy Market Report:

  • HOCM is often a diagnosis of the young, though with improvements in management and treatment, affected individuals are surviving to adulthood with greater frequency than in decades past. It is estimated that the average age of affected patients is 42 years, though differences in outcomes and risk of sudden cardiac death exist depending on age and age of diagnosis. Patients diagnosed in childhood were usually asymptomatic, but demonstrated a 5.9% annual mortality rate. [Burns et al., 2018]

  • As per the study conducted by Prinz et al. (2011), there are two types of HCM: a more common, obstructive type (HOCM, 70%) in which there is left ventricular outflow obstruction and a less common, non-obstructive type (HNCM). The extent and localization of the wall thickening are highly variable in HNCM.

  • As per the article by Marian et al. (2017), prevalence of HCM has been estimated at 0.16% to 0.29% in the general adult population.

Key benefits of the report:

  1. Hypertrophic Cardiomyopathy market report covers a descriptive overview and comprehensive insight of the Hypertrophic Cardiomyopathy Epidemiology and Hypertrophic Cardiomyopathy  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Hypertrophic Cardiomyopathy market report provides insights on the current and emerging therapies.

  3. Hypertrophic Cardiomyopathy market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Hypertrophic Cardiomyopathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hypertrophic Cardiomyopathy market.

Got queries? Click here to know more about the Hypertrophic Cardiomyopathy Market Landscape.

Hypertrophic Cardiomyopathy Overview

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). HCM occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. The ventricle size often remains normal, but the thickening may block blood flow out of the ventricle. If this happens, the condition is called Obstructive hypertrophic cardiomyopathy (HOCN). Sometimes the septum, the wall that divides the left and right sides of the heart, thickens and bulges into the left ventricle. This can block blood flow out of the left ventricle. Then the ventricle must work hard to pump blood. Symptoms can include chest pain, dizziness, shortness of breath, or fainting.

Hypertrophic Cardiomyopathy Market 

The dynamics of the Hypertrophic Cardiomyopathy market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Bristol Myers Squibb, Cytokinetics, Novartis, Bristol Myers Squibb, Celltrion, Palatin Technologies, and others during the forecasted period 2018-2030.

Hypertrophic Cardiomyopathy Pipeline Therapies and Key Companies 

  • Mavacamten: Bristol Myers Squibb

  • CK-274: Cytokinetics

  • LCZ-696: Novartis

  • MYK-224: Bristol Myers Squibb

  • CT-G20: Celltrion

  • PL-5028: Palatin Technologies 

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Hypertrophic Cardiomyopathy Patient Share (%) Overview at a Glance

5. Hypertrophic Cardiomyopathy Market Overview at a Glance

6. Hypertrophic Cardiomyopathy Disease Background and Overview

7. Hypertrophic Cardiomyopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypertrophic Cardiomyopathy 

9. Hypertrophic Cardiomyopathy Current Treatment and Medical Practices

10. Unmet Needs

11. Hypertrophic Cardiomyopathy Emerging Therapies

12. Hypertrophic Cardiomyopathy Market Outlook

13. Country-Wise Hypertrophic Cardiomyopathy Market Analysis (2018-2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Hypertrophic Cardiomyopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Hypertrophic Cardiomyopathy Market Outlook 2030. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles